We’ve covered several cardiology topics over the years in previous posts, including heart failure and LVADs, but we (and our guest posters) never quite mustered the courage to tackle Acute Coronary Syndrome. Until today. Today we bring you the tl;dr overview of ACS!
Read MoreEver been totally immersed in the methods section of a study paper and wondered, “Why are there so many endpoints? What does it all MEAN?!” Yeah, us too. Which is why we’re going to try to make this essential part of trial endpoint evaluation just a smidge more clear for you.
Read MoreWith new drugs entering the market all the time and drug prices rapidly increasing, we have to ask the tough question - is the drug worth the cost? Although this question is rarely easy or straightforward to answer, we do have tools available to us to shed some light. Let tl;dr introduce you to the world of pharmacoeconomics!
Read MoreChildren are just tiny humans, right? Munchkins who function identically to adults, just on a smaller scale? NOT! Today we’re introducing you to a couple reasons why this isn’t true and then reviewing management of several classic pediatric illnesses.
Read MoreThe p-value and power are the holy grails of statistical significance, right? Let’s make sure you understand them (and how they can be exploited). This article may blow your mind. Journal club just got a whole lot more interesting…
Read MoreFirst there were regular insulins, then intermediate-acting NPH insulins, then long-acting, and most recently ultra long-acting, which is actually still a daily product. So what’s this about a possible once-weekly insulin? Wouldn’t that blow the other so-called long-acting products out of the water? Perhaps it’s time to judge with journal club.
Read MoreWe spend 4+ years as pharmacists getting our bearings for managing human pharmacotherapy. So what happens when your patient is no longer human? Are there medications on your shelves right now that you might be able to use for your humans’ furry family members?
Read MoreUTIs are one of the most common infections you’ll encounter in both the inpatient and the outpatient world. There have been several new drugs approved in the last few years, and there has been a push towards shorter treatment durations. Get yourself caught up to speed with the latest and greatest in UTI treatment.
Read MoreOdds are that you may not have had a lecture on multiple sclerosis during pharmacy school, but this disease state is more common than previously realized. So you may very well encounter these medications at some point in your career. Plus, it is a HOT area for drug development with FOUR FDA approvals in 2020 alone!
Read MoreFebrile Neutropenia is one of the few oncologic emergencies. This post is a crash course in this difficult disease state that will leave you better prepared to treat your patients (even if you’re not an oncology specialist).
Read MoreU-500 insulin is Public Enemy #1 on the ISMP list. This post dispels the mystery behind concentrated insulin and helps you avoid errors when it comes across your computer screen (or on your NAPLEX)
Read MoreIn this pharmacology post, tl;dr is going to break down where the salt is in that convoluted distal convoluted tubule so that you know exactly how HCTZ works. You’ll also know what to watch for with this seemingly benign, very cheap, ubiquitous medication, as well as its cousins!
Read More
